CareDx, Inc
CDNA
Rang in aandelen
#4451
CareDx, Inc. is a global innovator specializing in the discovery, development,... CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
Aandeelprijs
$67.25
Laatst gesynchroniseerd: 2026-10-19
Marktkapitalisatie
$3.48B
Verandering (1 dag)
5.08%
Verandering (1 jaar)
341.85%
Land
US
Handel CareDx, Inc (CDNA)
Categorie
Healthcare
P/S-ratio voor CareDx, Inc (CDNA)
P/S-ratio op October 2026 TTM: 7.31
Volgens de meest recente financiële rapporten en aandelenkoers van CareDx, Inc is de huidige P/S-ratio (TTM) 7.31. Eind 2023 had het bedrijf een P/S-ratio van 2.30.
P/S-ratiohistoriek voor CareDx, Inc van 2012 tot 2026
P/S-ratio aan het einde van elk jaar
| Jaar | P/S-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 7.31 | 115.51% |
| 2024 | 3.39 | 47.08% |
| 2023 | 2.30 | 21.73% |
| 2022 | 1.89 | -76.41% |
| 2021 | 8.02 | -54.25% |
| 2020 | 17.52 | 144.88% |
| 2019 | 7.16 | -38.85% |
| 2018 | 11.70 | 230.55% |
| 2017 | 3.54 | 222.93% |
| 2016 | 1.10 | -59.21% |
| 2015 | 2.69 | 74.01% |
| 2014 | 1.54 | -48.86% |
| 2013 | 3.02 | -7.45% |
| 2012 | 3.26 | 0.00% |
P/S-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/S-ratio | Verschil in P/S-ratio | Land |
|---|---|---|---|
| 5.37 | -26.47% |
US
|
|
| 6.29 | -13.88% |
US
|
|
| 21.02 | 187.71% |
US
|
|
| - | - |
CN
|
|
| 6.67 | -8.75% |
US
|
